Journal article · 2024 · Open access

Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance

Deus S. Ishengoma, Celine I. Mandara, Catherine Bakari, Abebe Alemu Fola, Rashid A. Madebe, Misago D. Seth, Filbert T. Francis, Creyton Buguzi, Ramadhan Moshi, Issa Ally Garimo, Samwel Lazaro, Abdallah Lusasi and 9 more

The Lancet Infectious Diseases, 24(11), 1225–1233 · Published 16 August 2024 · DOI 10.1016/s1473-3099(24)00362-1

Open full textCite this paper

In brief

“Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance” is a 2024 journal article by Deus S. Ishengoma and 20 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 143 citations as of 18 November 2026, which puts it in the top 1% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Infectious Diseases.

Citations
143
Most cited in
2026 (67)
Field-weighted impact
44.23
References
30
Authors
21

Abstract

Background In 2021, nationwide malaria molecular surveillance revealed a high prevalence of a validated artemisinin resistance marker, the kelch13 ( k13 ) Arg561His mutation, in the Kagera region of northwestern Tanzania. We aimed to investigate the efficacy of artemether–lumefantrine and artesunate–amodiaquine and to confirm the presence of artemisinin partial resistance (ART-R) in the Karagwe district of this region. Methods This single-arm, therapeutic efficacy study was carried out at the Bukangara dispensary in the Karagwe district of the Kagera region in northwestern Tanzania. Eligible participants were aged between 6 months and 120 months, had confirmed Plasmodium falciparum asexual parasitaemia, and met other inclusion criteria according to WHO's standard protocol. Participants were enrolled, treated sequentially with either artemether–lumefantrine or artesunate–amodiaquine, and assessed clinically and parasitologically for 28 days as per WHO protocol. Parasitaemia was measured every 8 h until day 3, on day 7, and then during weekly follow-up visits until day 28. Mutations in the k13 gene and extended haplotypes with the mutations were analysed, and comparisons were made with previous samples collected in the same region of Kagera and in Rwanda and southeast Asia. The primary endpoint was PCR-corrected cure rate. Findings Between April 29 and Sept 1, 2022, 343 patients were screened, of whom 176 were enrolled: 88 in each treatment group. The PCR-corrected cure rate was 98% (95% CI 91–100) in the artemether–lumefantrine group and 100% (96–100) in the artesunate–amodiaquine group. Persistent parasitaemia on day 3 occurred in 11 (13%) of 88 patients in the artemether–lumefantrine group and 17 (19%) of 88 patients in the artesunate–amodiaquine group. Arg561His mutations on day 0 and parasitaemia on day 3 were reported in eight (9%) of 87 patients in the artemether–lumefantrine group and ten (12%) of 86 patients in the artesunate–amodiaquine group. The median parasite clearance half-life in patients harbouring parasites with Arg561His mutation was 6·1 h in the artemether–lumefantrine group and 6·0 h in the artesunate–amodiaquine group. Parasites with the Arg561His mutation were not similar to those from southeast Asia and Rwanda but had similar haplotypes to parasites reported in the same Tanzanian region of Kagera in 2021. Interpretation This study confirms the presence of ART-R in Tanzania, although artemether–lumefantrine and artesunate–amodiaquine showed high efficacy. A context-specific response strategy and vigilance to detect the reduced efficacy of current antimalarial treatments and ART-R in other parts of the country are urgently needed. Funding The Bill & Melinda Gates Foundation and the US National Institutes of Health.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ishengoma, D. S., Mandara, C. I., Bakari, C., Fola, A. A., Madebe, R. A., Seth, M. D., Francis, F. T., Buguzi, C., Moshi, R., Garimo, I. A., Lazaro, S., Lusasi, A., Aaron, S., Chacky, F., Mohamed, A., Njau, R., Kitau, J., Rasmussen, C., Bailey, J. A., . . . Warsame, M. (2024). Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. The Lancet Infectious Diseases, 24(11), 1225–1233. https://doi.org/10.1016/s1473-3099(24)00362-1

MLA 9

Ishengoma, Deus S., et al. “Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance.” The Lancet Infectious Diseases, vol. 24, no. 11, 2024, pp. 1225–1233. https://doi.org/10.1016/s1473-3099(24)00362-1.

Chicago

Ishengoma, Deus S., Celine I. Mandara, Catherine Bakari, Abebe Alemu Fola, Rashid A. Madebe, Misago D. Seth, Filbert T. Francis, et al. 2024. “Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance.” The Lancet Infectious Diseases 24 (11): 1225–1233. https://doi.org/10.1016/s1473-3099(24)00362-1.

Harvard

Ishengoma, D. S. et al. (2024) ‘Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance’, The Lancet Infectious Diseases, 24(11), pp. 1225–1233. doi:10.1016/s1473-3099(24)00362-1.

IEEE

D. S. Ishengoma et al., “Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance,” The Lancet Infectious Diseases, vol. 24, no. 11, pp. 1225–1233, 2024, doi: 10.1016/s1473-3099(24)00362-1.

BibTeX

@article{ishengoma2024evidence,
  title     = {{Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance}},
  author    = {Ishengoma, Deus S. and Mandara, Celine I. and Bakari, Catherine and Fola, Abebe Alemu and Madebe, Rashid A. and Seth, Misago D. and Francis, Filbert T. and Buguzi, Creyton and Moshi, Ramadhan and Garimo, Issa Ally and Lazaro, Samwel and Lusasi, Abdallah and Aaron, Sijenunu and Chacky, Frank and Mohamed, Ally and Njau, Ritha and Kitau, Jovin and Rasmussen, Charlotte and Bailey, Jeffrey A. and Juliano, Jonathan J. and Warsame, Marian},
  journal   = {The Lancet Infectious Diseases},
  year      = {2024},
  volume    = {24},
  number    = {11},
  pages     = {1225--1233},
  doi       = {10.1016/s1473-3099(24)00362-1},
  url       = {https://doi.org/10.1016/s1473-3099(24)00362-1}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20241717
20255959
20266767

Its field-weighted citation impact is 44.23: it has been cited 44.23 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control

  • artemisinin resistance
  • Plasmodium falciparum
  • kelch13
  • artemether-lumefantrine
  • artesunate-amodiaquine
  • antimalarial drug efficacy
  • Kagera Region

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Ishengoma, D. S., Mandara, C. I., Bakari, C., Fola, A. A., Madebe, R. A., Seth, M. D., Francis, F. T., Buguzi, C., Moshi, R., Garimo, I. A., Lazaro, S., Lusasi, A., Aaron, S., Chacky, F., Mohamed, A., Njau, R., Kitau, J., Rasmussen, C., Bailey, J. A., . . . Warsame, M. (2024). Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. The Lancet Infectious Diseases, 24(11), 1225–1233. https://doi.org/10.1016/s1473-3099(24)00362-1

How many times has this paper been cited?

143 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Infectious Diseases: sign in and open the full text from this page.

Who wrote this paper?

Deus S. Ishengoma, Celine I. Mandara, Catherine Bakari, Abebe Alemu Fola, Rashid A. Madebe, Misago D. Seth, Filbert T. Francis, Creyton Buguzi, Ramadhan Moshi, Issa Ally Garimo, Samwel Lazaro, Abdallah Lusasi and 9 more.

What is the DOI of this paper?

10.1016/s1473-3099(24)00362-1, permanently at https://doi.org/10.1016/s1473-3099(24)00362-1. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.